がん性悪液質の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測

がん性悪液質の世界市場規模は、2024年の29億米ドルから2033年には46億2,000万米ドルに成長し、2026年から2033年の予測期間中に5.34％の堅調な年間平均成長率（CAGR）を示すと予測されます。

がん性悪液質市場は、がんの有病率の増加と、がんに伴う重篤な合併症としての悪液質に対する意識の高まりにより、大きく成長する見込みです。がん性悪液質は、重度の体重減少、筋肉の衰え、全身の健康状態の低下を特徴とする多因子症候群であり、患者のQOLと治療成績に大きな影響を与えます。ヘルスケアプロバイダーや研究者ががん治療における悪液質への対処の重要性を認識するにつれ、効果的な治療法や管理戦略に対する需要が高まり、この市場は堅調な拡大が見込まれます。現在の治療選択肢には、栄養介入、薬理学的薬剤、食欲と筋肉量の改善を目的とした支持療法などがあります。

さらに、がん性悪液質の根本的なメカニズムに関する調査と理解の進展が、市場内の技術革新を促進しています。悪液質に関与する特定のバイオマーカーや経路の同定は、この病態により効果的に対処できる標的療法の開発に道を開いています。例えば、抗炎症剤や蛋白同化ステロイドの研究は、潜在的な治療選択肢として注目を集めています。悪液質の生物学に関する新たな知見の発見が続く中、患者の転帰とQOLの改善が期待されることから、市場はさらに拡大する可能性が高いです。

さらに、がん治療における集学的アプローチが重視されるようになり、がん性悪液質の展望が形成されつつあります。ヘルスケア提供者が栄養サポート、理学療法、心理的ケアをがん治療計画に統合することの重要性をますます認識するようになり、包括的な悪液質管理ソリューションに対する需要が増加するとみられます。この傾向は、個別化医療の文脈では特に関連性が高く、個別化介入によってがん治療の有効性を大幅に高めることができます。がん性悪液質市場が進化を続ける中、革新的な治療オプション、全人的な患者ケアへの注力、継続的な研究の組み合わせが、今後の成長を促進する上で重要な役割を果たすと思われます。

当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をお客様に提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます：

市場概要：市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクション。

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、最終用途、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場プレイヤーの包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します￥。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 がん性悪液質産業分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 機会
• 業界動向
• ポーターのファイブフォース分析
• 市場の魅力分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 がん性悪液質の世界市場分析：治療薬別

• 治療薬別、概要
• 治療薬別、過去および予測データ分析
• 黄体ホルモン
• 副腎皮質ホルモン
• 併用療法
• その他

第6章 がん性悪液質の世界市場分析：作用機序別

• 作用機序別、概要
• 作用機序別、過去および予測データ分析
• 食欲刺激薬
• 体重減少安定剤
• その他

第7章 がん性悪液質の世界市場分析：流通チャネル別

• 流通チャネル別、概要
• 流通チャネル別、過去および予測データ分析
• 病院店舗
• 小売薬局店舗
• オンライン薬局

第8章 がん性悪液質の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋地域売上分析
  • 概要、実績と予測
  • アジア太平洋地域：セグメント別
  • アジア太平洋地域国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他アジア太平洋地域
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他ラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ国別一覧
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東とアフリカ

第9章 がん性悪液質企業の競合情勢

• がん性悪液質市場の競合
• 提携/協力/合意
• 合併・買収
• 新製品の発売
• その他の開発

第10章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• Aeterna Zentaris Inc.
• Alder BioPharmaceuticals Inc.
• Aphios Corporation
• Eli Lilly And Company
• GTxInc.
• Helsinn Group
• Merck & Co. Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• XBiotech Inc

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Therapeutics (USD MN)
• Progestogens Market Sales By Geography (USD MN)
• Corticosteroids Market Sales By Geography (USD MN)
• Combination Therapies Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Mechanism of Action (USD MN)
• Appetite Stimulators Market Sales By Geography (USD MN)
• Weight Loss Stabilizers Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Distribution Channel (USD MN)
• Hospital Stores Market Sales By Geography (USD MN)
• Retail Pharmacy Stores Market Sales By Geography (USD MN)
• Online Pharmacies Market Sales By Geography (USD MN)
• Global Cancer Cachexia Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Cancer Cachexia Report
• Market Research Process
• Market Research Methodology
• Global Cancer Cachexia Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Therapeutics
• Market Attractiveness Analysis By Mechanism of Action
• Market Attractiveness Analysis By Distribution Channel
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Therapeutics (USD MN)
• Progestogens Market Sales By Geography (USD MN)
• Corticosteroids Market Sales By Geography (USD MN)
• Combination Therapies Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Mechanism of Action (USD MN)
• Appetite Stimulators Market Sales By Geography (USD MN)
• Weight Loss Stabilizers Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Distribution Channel (USD MN)
• Hospital Stores Market Sales By Geography (USD MN)
• Retail Pharmacy Stores Market Sales By Geography (USD MN)
• Online Pharmacies Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis
• Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Global Cancer Cachexia Market size is anticipated to grow from USD 2.9 Billion in 2024 to USD 4.62 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.34% during the forecast period of 2026 to 2033.

The cancer cachexia market is poised for significant growth, driven by the increasing prevalence of cancer and the rising awareness of cachexia as a serious complication associated with the disease. Cancer cachexia is a multifactorial syndrome characterized by severe weight loss, muscle wasting, and a decline in overall health, significantly impacting patients' quality of life and treatment outcomes. As healthcare providers and researchers recognize the importance of addressing cachexia in cancer care, the demand for effective therapies and management strategies is expected to rise, positioning this market for robust expansion. Current treatment options include nutritional interventions, pharmacological agents, and supportive care measures aimed at improving appetite and muscle mass.

Moreover, advancements in research and understanding of the underlying mechanisms of cancer cachexia are driving innovation within the market. The identification of specific biomarkers and pathways involved in cachexia is paving the way for the development of targeted therapies that can more effectively address this condition. For instance, the exploration of anti-inflammatory agents and anabolic steroids is gaining traction as potential treatment options. As research continues to uncover new insights into the biology of cachexia, the market is likely to expand further, driven by the promise of improved patient outcomes and quality of life.

Additionally, the growing emphasis on multidisciplinary approaches to cancer care is shaping the cancer cachexia landscape. As healthcare providers increasingly recognize the importance of integrating nutritional support, physical therapy, and psychological care into cancer treatment plans, the demand for comprehensive cachexia management solutions is likely to increase. This trend is particularly relevant in the context of personalized medicine, where tailored interventions can significantly enhance the effectiveness of cancer therapies. As the cancer cachexia market continues to evolve, the combination of innovative treatment options, a focus on holistic patient care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Therapeutics

• Progestogens
• Corticosteroids
• Combination Therapies
• Others

By Mechanism of Action

• Appetite Stimulators
• Weight Loss Stabilizers
• Others

By Distribution Channel

• Hospital Stores
• Retail Pharmacy Stores
• Online Pharmacies
• COMPANIES PROFILED
• Aeterna Zentaris Inc.
• Alder BioPharmaceuticals Inc.
• Aphios Corporation
• Eli Lilly and Company
• GTxInc.
• Helsinn Group
• Merck & Co. Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• XBiotech Inc.
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CANCER CACHEXIA INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutics
  • 3.7.2 Market Attractiveness Analysis By Mechanism of Action
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY THERAPEUTICS

• 5.1. Overview By Therapeutics
• 5.2. Historical and Forecast Data Analysis By Therapeutics
• 5.3. Progestogens Historic and Forecast Sales By Regions
• 5.4. Corticosteroids Historic and Forecast Sales By Regions
• 5.5. Combination Therapies Historic and Forecast Sales By Regions
• 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY MECHANISM OF ACTION

• 6.1. Overview By Mechanism of Action
• 6.2. Historical and Forecast Data Analysis By Mechanism of Action
• 6.3. Appetite Stimulators Historic and Forecast Sales By Regions
• 6.4. Weight Loss Stabilizers Historic and Forecast Sales By Regions
• 6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Stores Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacy Stores Historic and Forecast Sales By Regions
• 7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER CACHEXIA COMPANIES

• 9.1. Cancer Cachexia Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF CANCER CACHEXIA INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Aeterna Zentaris Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Alder BioPharmaceuticals Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Aphios Corporation
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Eli Lilly And Company
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. GTxInc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Helsinn Group
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Merck & Co. Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Novartis AG
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Bristol-Myers Squibb Company
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. XBiotech Inc
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies